Our mission is to develop disease-modifying therapies to stop or reverse the progression of neurodegenerative diseases to address the unmet medical need.
-
Highlight
Webcast: Update on Phase 2 preparation, Tuesday 2 June 2026
-
Highlight
Herantis Pharma – equity proposition (by Edison Group)
-
Highlight
Herantis Pharma Plc Annual report 2025
-
Highlight
FY 2025 report webcast
-
Highlight
Herantis Pharma Phase 1b biomarker data webcast
-
Highlight
Topline Phase 1b data webcast
-
Highlight
Edison TV interview with Herantis CEO, Antti Vuolanto